Actuate Therapeutics, Inc. (ACTU)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.48+8.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ACTU
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ACTU — legal / regulatory event — Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard;…
Dated 2026-07-17
Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing. On July 15, 2026, Actuate Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that that from June 1, 2026 to July 14, 2026, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on The Nas…
Why it matters: Improving operating losses would show progress in managing costs and cash flow. This is crucial for investor confidence.
Supportive ifOperating income improves to less than -$5.0 million in Q2 2026.
Worry ifOperating income remains worse than -$5.0 million in Q2 2026.
Why it matters: Getting more capital is important for operations after mid-2026. Without it, the company may have big problems.
Worry ifA press release or announcement will confirm raising at least $10 million in capital.
Less concerning ifIf no capital is raised by mid-2026, there may be operational issues.
Why it matters: New data could show how well elraglusib works with other treatments. This could expand its use in cancer therapy.
Watch forElraglusib with RAS inhibitors has good preclinical results. These results will be shared in mid-2026.
Also watch forThe combination has bad or unclear preclinical results. This is a concern.
Why it matters: The company must keep its listing. This is important for investor trust and access to funds.
Worry ifThe company met Nasdaq's listing rules. This restored its market value above $50 million.
Less concerning ifNot meeting Nasdaq's rules could lead to delisting.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$364 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $1,003 loss on $10,000 · 10.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,860 loss on $10,000 · 88.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Getting more money is important for Actuate. It helps them keep running after mid-2026.
Supportive ifLook for news about a new funding round or an investment over $5 million.
Worry ifNo new funding sources identified by the end of Q3 2026.
Why it matters: Getting funding is very important. It helps keep operations running and clinical programs moving forward. Without it, the company may face big problems.
Worry ifActuate announces it has raised money or made a financing deal.
Less concerning ifIf no funding is secured, clinical programs may be delayed.
Why it matters: Actuate needs more funds to continue its work. Success in raising capital is crucial for its future.
Worry ifActuate raises more money before mid-2026.
Less concerning ifActuate does not get the needed funding, causing delays or cutbacks.
Why it matters: Starting this study is important. It will show if the oral form works for advanced cancers.
Supportive ifThe Phase 1/2 study for oral elraglusib begins as planned in the second half of 2026.
Worry ifThe study initiation is delayed beyond 2026 or canceled.
Why it matters: Keeping the Nasdaq listing is important for trust and access to money.
Worry ifActuate gets confirmation that it meets Nasdaq listing rules.
Less concerning ifFurther notices of delisting or failure to meet listing standards are issued.